The Foundational Concept: Cells organize biochemistry through liquid droplets membraneless organelles formed by phase separation. Disease mutations convert these dynamic liquids into solid pathology, seeding irreversible aggregates.

The Mechanism:

Physiological Condensates: Proteins with low-complexity domains (TDP-43, FUS, tau, α-synuclein) undergo liquid-liquid phase separation, forming dynamic droplets stress granules, nucleoli, P-bodies. These concentrate reactions without membranes.

Concentration Effect: Inside droplets, protein concentration increases 10-100x. This facilitates interactions but also creates aggregation risk molecules packed tightly, primed for transition.

Maturation Cascade: Liquid droplets are metastable. Over time or with stress, they transition through stages liquid → hydrogel (reversible gel) → solid aggregate (irreversible). Water excluded, β-sheet content increases.

Mutation Acceleration: Disease-linked mutations (TDP-43 ALS mutations, FUS mutations, tau FTDP-17) lower the barrier for phase separation and accelerate liquid-to-solid transition. They make droplets stickier, more viscous, prone to gelation.

Seeding Competence: Matured solid aggregates become seeds they escape degraded droplets, enter extracellular space, and template aggregation in neighboring cells. Prion-like propagation follows.

Function Loss: When proteins solidify into aggregates, they cannot perform normal droplet functions RNA metabolism, stress response, transport. Cells lose essential biochemistry.

The Physical Chemistry:

Phase separation driven by multivalent interactions

RNA modulates droplet dynamics

Post-translational modifications (phosphorylation, acetylation) regulate transition

ATP dissolves droplets via chaperone activity

Disease Specificity:

ALS: TDP-43, FUS droplet maturation

AD: Tau droplet-to-fibril transition

PD: ��-Synuclein liquid condensates

HD: Huntingtin fragments phase separate

Therapeutic Implications:

ATP enhancement dissolving pathological droplets

Chaperone upregulation (Hsp70) preventing maturation

Phase separation modifiers (small molecules altering interfacial tension)

RNA-based therapeutics restoring normal droplet regulation

This reframes proteinopathies as phase transition disorders dynamic liquids solidify into pathological solids.